Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

Abstract

Background Ipilimumab is a human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen 4 and has shown promising activity in advanced melanoma. We aimed to ascertain the antitumour efficacy of ipilimumab in patients with advanced melanoma.Methods We undertook a randomised, double-blind, phase 2 trial in 66 centres from 12 countries. 217 patients with previously treated stage III (unresectable) or stage IV melanoma were randomly assigned a fixed dose of ipilimumab of either 10 mg/kg (n=73), 3 mg/kg (n=72), or 0.3 mg/kg (n=72) every 3 weeks for four cycles (induction) followed by maintenance therapy every 3 months. Randomisation was done with a permuted block procedure, stratified on the basis of type of previous treatment. The primary endpoint was best overall response rate (the proportion of patients with a complete or partial response, according to modified WHO criteria). Efficacy analyses were done by intention to treat, whereas safety analyses included patients who received at least one dose of ipilimumab. This study is registered with ClinicalTrials.gov, number NCT00289640.Findings The best overall response rate was 11.1% (95% CI 4.9-20.7) for 10 mg/kg, 4.2% (0.9-11.7) for 3 mg/kg, and 0% (0.0-4.9) for 0.3 mg/kg (p=0.0015; trend test). Immune-related adverse events of any grade arose in 50 of 71, 46 of 71, and 19 of 72 patients at doses of 10 mg/kg, 3 mg/kg, and 0.3 mg/kg, respectively; the most common grade 3-4 adverse events were gastrointestinal immune-related events (11 in the 10 mg/kg group, two in the 3 mg/kg group, none in the 0.3 mg/kg group) and diarrhoea (ten in the 10 mg/kg group, one in the 3 mg/kg group, none in the 0.3 mg/kg group).Interpretation Ipilimumab elicited a dose-dependent effect on efficacy and safety measures in pretreated patients with advanced melanoma, lending support to further studies at a dose of 10 mg/kg.Funding Bristol-Myers Squibb.

Overview

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(09)70334-1

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

1 retracted

Show all 28 references

Cited by

See all 1,195

Metadata

Authors
Wolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., Grob, J.-J., Chesney, J., Chin, K., Chen, K., Hoos, A., O'Day, S. J., & Lebbé, C.
Affiliations
  • Memorial Sloan Kettering Cancer Center (US)
  • Universitair Ziekenhuis Brussel (BE)
  • Washington University in St. Louis (US)
  • Mount Sinai Medical Center (US)
  • Essen University Hospital (DE)
  • University of Alberta (CA)
  • Baptist Cancer Center (US)
  • Hôpital Sainte-Marguerite (FR)
  • University of Louisville (US)
  • Bristol-Myers Squibb (United States) (US)
  • Angeles Clinic and Research Institute (US)
Corresponding author
Wolchok, Jedd D
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2010-02
Volume
11
Issue
2
Pages
155-164
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2095826876
Cited by
1,195
References
28
Citations by year
2026: 13 · 2025: 34 · 2024: 44 · 2023: 60 · 2022: 56 · 2021: 57 · 2020: 92 · 2019: 84 · 2018: 84 · 2017: 102 · 2016: 112 · 2015: 103 · 2014: 84 · 2013: 95 · 2012: 71
FWCI
28.69
Type
journal article
Language
en
Update notices
erratum (2010-03-01)
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • VUBIR (Vrije Universiteit Brussel) (submittedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Keywords
ipilimumab, advanced melanoma, CTLA-4 blockade, dose-ranging, immune-related adverse events, immune-related colitis, best overall response rate, maintenance therapy, antitumour efficacy, immunotherapy safety, dose-dependent effects, diarrhea, immune-related hepatitis, immune-related pneumonitis
MeSH terms
Ipilimumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Melanoma, Middle Aged, Skin Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. https://app.cochat.ai/papers/10.1016/s1470-2045(09)70334-1
The paper
Wolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., Grob, J.-J., Chesney, J., Chin, K., Chen, K., Hoos, A., O'Day, S. J., & Lebbé, C. (2010). Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(09)70334-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.